Overview

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Status:
COMPLETED

Trial end date:
2024-09-23

Target enrollment:

Participant gender:

Summary

To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis

Phase:

PHASE1

Details

Lead Sponsor:

Sun Pharmaceutical Industries, Inc.

Treatments:

ruxolitinib